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Glutamine:fructose-6-phosphate amidotransferase (GFAT) is a rate-limiting enzyme in the hexo-
amine biosynthetic pathway and plays an important role in type 2 diabetes. We now report the ﬁrst
structures of the isomerase domain of the human GFAT in the presence of cyclic glucose-6-phos-
phate and linear glucosamine-6-phosphate. The C-terminal tail including the active site displays a
rigid conformation, similar to the corresponding Escherichia coli enzyme. The diversity of the CF
helix near the active site suggests the helix is a major target for drug design. Our study provides
insights into the development of therapeutic drugs for type 2 diabetes.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction mals. Glucose integration through the hexosamine biosyntheticInsulin resistance caused by sustained hyperglycemia is a hall-
mark of type 2 diabetes, uncontrolled type 1 diabetes, obesity and
the metabolic syndrome. Substantial data suggest that glucose tox-
icity in diabetes may be mediated through increased oxidative
stress. The overproduction of superoxide through the mitochon-
drial electron transport process is considered a unifying mecha-
nism accountable for abnormalities in several biochemical
pathways, one of which is the hexosamine biosynthetic pathway
[1].
The ﬁrst step in the de novo biosynthesis of hexosamines, the
formation of glucosamine-6-phosphate (GlcN6P) from fructose-6-
phosphate (Fru6P) and glutamine, is catalyzed by the rate-limiting
enzyme glutamine:fructose-6-phosphate amidotransferase (GFAT),
also known as GlmS, Gfa or GFAT according to the enzyme source
[2]. The reaction end-product of the pathway, uridine diphospho-
N-acetyl D-glucosamine, is an essential inhibitor of myriad amino
sugar, including peptideglicans and lipopolysaccharides in bacte-
ria, chitin and mannoproteins in fungi and glycoproteins in mam-chemical Societies. Published by E
ate amidotransferase; Fru6P,
lcN6P, glucosamine-6-phos-
Y. Nakaishi).pathway in mammals is regarded as a cellular nutrient sensor
and this pathway is one of the mechanisms through which hyper-
glycemia mediates peripheral insulin resistance [3] and diabetic
complications [4]. The enhanced activity of human GFAT has been
implicated in insulin resistance in cellular and animal models [5–
7]. Thus, human GFAT is recognized as an interesting potential tar-
get for type 2 diabetes complications in medicinal chemistry [8]. In
addition, structural differences between the bacterial, fungal, and
mammalian enzymes of GFAT may lead to the design of therapeu-
tic antibacterial and antifungal drugs [9].
Human GFAT is highly expressed in adipocytes and skeletal
muscle. Two different proteins and a splice variant encoded by
GFAT genes were identiﬁed in humans, known as GFAT1, GFAT2
and GFAT1-L, respectively [10,11]. Their deduced amino acid se-
quences share approximately a 75% identity. The differential
expression patterns of these isozymes of GFAT would allow it to
function differently based on the type of various tissues.
GFAT involves two structurally and functionally distinct
domains. The N-terminal 27 kDa glutaminase domain catalyses
the hydrolysis of glutamine to glutamate and ammonia. The C-ter-
minal 40 kDa isomerase domain utilizes ammonia for the conver-
sion of Fru6P to GlcN6P. The bacterial counterpart (GlmS) of the
enzyme has been extensively studied [12–15]. Based on structural
and biochemical analyses, Escherichia coli GlmS is a functional
dimer and the glutaminase and isomerase domains are connectedlsevier B.V. All rights reserved.
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sible for ammonia transfer between the two domains. In a recently
reported structural study of the fungal counterpart, Gfa from Can-
dida albicans shows that it forms a tetramer as a dimer composed
of tight dimers, the structure of which is similar to that of E. coli
GlmS [16].
The three-dimensional structure of the human GFAT1 is indis-
pensable for understanding the general principles of catalysis in
the hexosamine biosynthetic pathway. In this paper, we describe
the crystal structures of the isomerase domain of the human
GFAT1 in complex with the cyclic glucose-6-phosphate (Glc6P)
and linear GlcN6P. This is the ﬁrst report of the GFAT1 structure
from mammalian sources. Considering the recent implication of
the pathway as one of the routes responsible for the type 2 diabe-
tes complications, the structural information of human GFAT1
could be exploited in order to design speciﬁc inhibitors as potential
drugs.
For clarity, GlmS, Gfa and GFAT1 refer to the GFATs from E. coli,
C. albicans and human, respectively, in this paper.
2. Materials and methods
2.1. Cloning, expression and puriﬁcation of recombinant human GFAT1
The cDNA of the isomerase domain of human GFAT1 (residues
Gln313–Glu680) was subcloned into the expression vector pET23
with an additional hexa-histidine tag at the 50-end. The construct
was then transformed into E. coli BL21(DE3)pLysS cells for IPTG-in-
duced overexpression. The cell pellet was resuspended in ice-cold
lysis buffer containing 10 mM Tris–HCl pH 8.0 and 5 mM b
mercaptoethanol. After sonication, the disrupted debris was re-
moved by centrifugation. The recombinant GFAT1 isomerase do-
main was puriﬁed using Ni-NTA afﬁnity gels and a fraction
containing proteins was collected followed by mixing with 1 mM
Fru6P or linear GlcN6P, namely, 2-deoxy-2-amino-glucitol-6-phos-
phate (AGP), as the ﬁnally puriﬁed material.
2.2. Crystallization, data collection and processing
Crystallization experiments were carried out by the hanging-
drop vapor diffusion method. Suitable crystals were obtained atTable 1
Data collection and reﬁnement statistics.
GFAT1 + Glc6P GFAT1 + AGP
Data collection
Space group I4122 I4122
Unit cell parameters a = b = 78.65,
c = 274.48
a = b = 78.93,
c = 277.32
Resolution range (Å) 29.9–1.90 (2.0–1.9) 39.5–2.20 (2.32–2.20)
Completeness (%) 99.1 (98.0) 98.4 (99.7)
Rsym 0.065 (0.301) 0.080 (0.183)
I/r(I) 6.0 (2.4) 6.0 (3.7)
Number of observed
reﬂections
264634 175674
Number of unique reﬂections 32485 21357
Reﬁnement
Rcryst/Rfree 18.7/21.7 16.0/20.5
Number of reﬁned atoms
Protein atoms 2866 2863
Solvent atoms 277 267
Substrate atoms 16 16
Rms deviations from ideality
Bonds (Å) 0.017 0.021
Angles () 1.805 1.778
Average B-factor (Å2) 20.90 20.57
The values in parentheses are for the highest resolution bin.20 C from the reservoir solution consisting of 12% isopropanol,
0.8 M ammonium acetate and 40 mM Tris–HCl at pH 8.5. After
soaking in reservoir buffer containing 25% (v/v) glycerol, the crystal
was ﬂash-frozen in liquid nitrogen. Data were collected on BL32B2
at SPring-8 (Hyogo, Japan), to a maximum resolution beyond 1.9 Å
for the GFAT1–Glc6P complex and 2.2 Å for the GFAT1–AGP com-
plex, and processed using the HKL2000 package [17]. The crystals
belong to the tetragonal space group I4122 and contain one mole-
cule/asymmetric unit. A summary of the statistics is provided in
Table 1.
2.3. Structure determination and reﬁnement
The structures were solved by molecular replacement with
MOLREP from the CCP4 suite [18] using the coordinates of GlmS
(PDB ID 1MOS) as a search model. The structures of the GFAT1-
substrate complexes were reﬁned using REFMAC5. Manual
rebuilding of the models and electron density map interpretation
were carried out using XtalView [19]. The ﬁnal models have R val-
ues of Rcryst = 18.7%/Rfree = 21.7% for the GFAT1–Glc6P complex and
R values of Rcryst = 16.0%/Rfree = 20.5% for the GFAT1–AGP complex
(Table 1). Simulations of the homology model of the full-length
GFAT1 were performed using MOE (CCG Co. Ltd.) with the full-
length GlmS structure (PDB ID 1MOR) as a template.3. Results and discussion
3.1. Overall structure of human GFAT1 isomerase domain
With the E. Coli GlmS structure as a search model, the structures
of the GFAT1 isomserase domain complexed with Glc6P and AGP
have been solved and reﬁned. The ﬁnal models contain residues
316–608 of GFAT1 (the N-terminal residues 313–315 are missing
in the density map), water molecules and a substrate (Glc6P or
AGP) (Table 1).
The isomerase domain of GFAT1 is dominated by two topologi-
cally similar subdomains, which are composed of residues 313–
493 and 494–508 (Fig. 1A). Each subdomain includes a ﬁve-
stranded parallel b sheet ﬂanked by a helices, building an a/b/a
Rossmann-like fold characteristic of nucleotide binding proteins.
The amino acid sequence of the isomerase domain of GFAT1 has
a 43% identity with GlmS and 63% identity with Gfa, respectively.
The overall structure of GFAT1 is similar to those of GlmS and
Gfa. This domain is also superimposed with the equivalent part
in GlmS with an rmsd of 2.44 Å. Likewise, the domain is superim-
posed with the equivalent part without the disordered His-loop
and C-tail in Gfa with an rmsd of 1.42 Å. Compared with the N-ter-
minal subdomain of the isomerase domain, the C-terminal adopts a
somewhat deviated conformation from the corresponding regions
in GlmS and Gfa, which is notably observed in the CF and CG heli-
ces and the C5 strand.
The GFAT1 isomerase domain in the crystals forms a dimer
related by 2-fold symmetry such as that in GlmS and a half of
the tetramer in Gfa [13–16]. The dimer interface of GFAT1 is
dominated by hydrogen bonds and predominantly stabilized by
interactions between the helices NE and NF of one subunit and
the helices CE and CF of the other (Fig. 1B).
3.2. Substrate-binding
The isomerase domain was co-crystallized with the cyclic Fru6P
or AGP. The electron density map clearly revealed the replacement
of the cyclic Fru6P to cyclic Glc6P. This is the product converted by
this enzyme reaction itself. This ﬁnding is consistent with the pre-
vious observations from GlmS that the isomerase domain can cat-
Fig. 1. Structure of the isomerase domain of human GFAT1. (A) Ribbon diagram of the structure of the GFAT1 isomerase domain. Secondary structural elements are labeled.
Glc6P is shown as a ball-and-stick model. (B) The dimer in the crystal is related by a 2-fold symmetry.
Fig. 2. Structure of the isomerase active site of GFAT1. (A) The AGP binding active site with chains colored in green from one subunit and in cyan from the other. Water
molecules are indicated by red spheres. Hydrogen bonds are shown as yellow dashed lines. (B) Structure-based sequence alignment of the isomerase domains of human
GFAT1, E. coli GlmS and C. albicans Gfa. Residues in GFAT1 involved in the Glc6P binding are indicated with red. Identical residues between GFAT1, Gfa and GlmS are colored
yellow. The violet and green frames show the His-loop and C-tail, respectively.
Y. Nakaishi et al. / FEBS Letters 583 (2009) 163–167 165alyze the conversion of Fru6P into Glc6P [14]. It also indicates that
the recombinant GFAT1 isomerase domain retains the enzymatic
activity. The binding patterns for both substrates in GFAT1 are al-most identical to the interactions previously reported in GlmS
[13,14]. The binding site of the substrates is formed by the
loops including the C-tail from the one subunit and the His-loop
166 Y. Nakaishi et al. / FEBS Letters 583 (2009) 163–167protruding from the other (Fig. 2A). The C-tail of GFAT1 is well de-
ﬁned and the density map of the His-loop is clearly visible, con-
trary to the expectation based on the preceding structural
analysis for the enzyme from C. albicans that the eukaryotic C-tail,
which is conserved among the eukaryotes (Fig. 2B), is disordered
and ﬂexible [16].
Structural arrangements of the enzyme around the 6-phosphate
for both substrates are identical. The 6-phosphate group estab-
lishes hydrogen bonds with Ser376, Ser420, Gln421, Ser422 and
Thr425 and several water molecules. Interactions of the sugar with
the protein are divergent depending on the speciﬁcation of the
substrate. In the structure containing the cyclic Glc6P, interactions
of the sugar ring with the protein are mainly mediated by water
molecules. The sugar ring is directly hydrogen-bonded with
Thr375, Val471, and Ala674, and with His576 from the neighboring
subunit. In the structure complexed with AGP, a linear GlcN6P is
bound to the protein substantially through water molecules. The
direct glucosamine–protein interactions involve the mainchain
atoms of Thr375, Val471, Ser473, Lys557 and Gln560 (Fig. 2A).
3.3. The CF helix near the active site
Large differences between GFAT1, Gfa and GlmS are seen in the
structures of the corresponding CF and CG helices, and C5 strand,
which are not well conserved and have high B factors (Figs. 2B
and 3A). Superposition of the GFAT1 isomerase domain with the
corresponding GlmS structure shows that the relative angle be-
tween the CF helices is 15, which is a lower value than 30 be-
tween the Gfa and GlmS CF helices. Although the CF helix, which
interacts with the His-loop participating in the formation of the
substrate-binding site with the C-tail, has been thought to be in-
volved in the ﬂexibility of the C-tail [16], the C-tail in GFAT1 is
properly ordered unlike the disordered state of that in Gfa. The
two structures of the C-tails observed in GFAT1 and Gfa might ex-
hibit distinct metastable or stable transition conditions during the
reaction. The structures of the corresponding CG helix beside the
CF helix are not preserved (Fig. 3A). The position and ﬂexibility
of the CG helix could be associated with the value of the relative
angle between the CF helices. The CF and CG helices, which are
found to hold different conformations between human, E. coli
and C. albicans, are located near the His-loop and C-tail involved
in the substrate-binding. The arrangements of these helices might
be implicated in the origin-selective recognition for the substrates
and have a biological signiﬁcance.Fig. 3. Comparison with other GFAT enzymes. (A) Superimposition of the isomerase activ
Homology model of the full-length human GFAT1. The model containing the glutaminase
(PDB ID 1JXA). The isomerase and glutaminase domains are represented in green and yTo better understand the implications of the CF helix, we have
generated the full-length GFAT1 by homology modeling based on
the structure of the full-length GlmS [20–22]. The homology model
shows that the CF helix interacts with the glutaminase domain and
the interface of the CF helix and glutaminase domain is located
near the glutamine binding site (Fig. 3B). The interface between
two domains as well as the Glc6P binding site and the glutamine
binding site could be the target regions of the enzyme inhibitor.
The fact that the CF helix is related to these three candidates sup-
ports the fact that the helix is a key regulator for the new strategy
of high-selective drug design. The structural difference in the CF
helix depending on the organism species might affect the enzyme
activity rates. The glutaminase domain of the human GFAT1 con-
tains a unique insertion and a potential phosphorylation site,
Ser243 [23], and these regions are locations distant from the isom-
erase domain. For a better understanding of the molecular mecha-
nisms of GFAT1, it is necessary to solve the crystal structure of the
full-length GFAT1.
3.4. Oligomerization
Previous studies involving gel ﬁltration and equilibrium ultra-
centrifugation have shown that the full-length of the human
GFAT1 exists as a tetramer in solution [24]. Similar results were
obtained for the rat liver enzyme [25]. In contrast, we obtained
a symmetric dimer structure in the crystalline state. Based on
the crystal structure of the tetramer of Gfa from C. albicans, the
interactions responsible for the tetramerization would be weaker
than those for the dimerization. Assuming that these weak inter-
actions at the tetramer interface are not maintained in the crystal
due to the crystal packing, therefore, the dimeric form is sug-
gested to be present. Notably, our structure is a dimeric form such
as that of the E. Coli GlmS, and the active site of the human GFAT1
is similar to that of the GlmS. This suggests that the dimer struc-
ture of the human GFAT1 is a biologically-relevant state.
During the preparation of this paper, the other crystal structure
of the isomerase domain of human GFAT1 was recently deposited
in the Protein Data Bank database (accession code 2V4M) in Sep-
tember 2008 (unpublished results). This crystal structure shows a
tetramer in the asymmetric unit with the C-tails disordered. The
structure of the active site as well as the quaternary organization
is similar to that of Gfa from C. albicans rather than our structure.
The other parts including the CF helix of this structure can be
superposed on our structure. This supports the above hypothesese sites of GFAT1 (green), GlmS (PDB ID 1MOR, gray) and Gfa (PDB ID 2PUW, pink). (B)
domain was built on the basis of the crystal structure of the full-length E. coli GlmS
ellow, respectively. Glc6P and glutamine are indicated by ball-and-stick models.
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that a modulation of the CF helix is signiﬁcant for the generation
of species-speciﬁcities. In addition, the C-tail might be related to
the oligomerization state.
In summary, we describe for the ﬁrst time, the structures of
the isomerase domain of the human GFAT1, which is the rate-
limiting enzyme important for metabolic control of amino sugar
biosynthesis. The structures reveal that the unexpected features
surrounding the active sites with the C-tail and His-loop are
properly ordered and involved in the substrate-binding. Consid-
ering recent studies, the human enzyme is assumed to be in at
least two different oligomerization states during the reaction
process. The ﬁndings from our study provide useful insights
into pharmacologic therapy for type 2 diabetes based on the
structure-based drug design of the enzymatic activity inhibitor.
The positions of the CF and CG helices related to the active site
are different from those of other organisms. These large struc-
tural divergences could lead to the development of a selective
drug.
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